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Over the last few years, the Research in 
Practice section of Archives of Disease 
in Childhood, Education & Practice has 
published papers covering a range of 
methods from basic science to clinical 
trials as well as initiatives developed to 
improve implementation and education 
of research skills. This article attempts 
to show how such diverse approaches fit 
together to work to improve patient care. 
Figure 1 provides a visual representation 
of how the different aspects, types and 
components of research work together. 
In the following sections, we explore 
how advances in different areas are trans-
forming our understanding of disease and 
how we look after and treat patients.
Understanding disease 
pathogenesis
The last two decades have seen an explo-
sion in technologies and methodologies, 
enabling us to further understand the 
pathophysiology of disease. Most notably, 
the development of ‘omic’ technologies 
has enabled high throughput analysis of 
the genetic, transcriptomic, proteomic 
and microbiomic landscape of patients 
and their diseases (see, eg, What is next 
generation sequencing?1–4). We will see 
below how this is impacting on diagnostics 
and treatments for patients. These tech-
nologies, at the most, provide a profile 
of a given disease or state; however, it is 
through functional evaluation in model 
systems, such as cell culture and animal 
models that we begin to further under-
stand their functional significance. The 
ability to manipulate the genome using 
technologies such as CRISPR/Cas95 has 
greatly advanced our ability to generate 
and test hypotheses with such models. It 
is in these models that many therapies are 
first conceived and tested. In the article, 
using animal models to improve care of 
neonatal encephalopathy,6 the authors 
elegantly show how use of animal models 
was critical in the developing and trans-
lating therapeutic hypothermia from a 
research hypothesis to standard clinical 
care for neonatal encephalopathy.
Understanding clinical 
challenges
In addition to the biology, understanding 
the clinical presentation, current treat-
ments and infrastructure is also essential. 
In neonates, the neonatal national research 
database7 perhaps gives us a gold standard 
of how routine care and data collection 
can be combined giving us ‘real world’ 
data of patient characteristics, current 
management and outcomes. Improved 
questionnaire- based and qualitative 
approaches8 are also a key component 
to getting a full picture of how diseases 
affect patients, and the challenges they 
face, helping keep research relevant to 
patients ideas, concerns and expectations.
improving diagnostics
The molecular approaches described in the 
papers above are now in routine practice 
for many patients. Targeted sequencing 
is commonly used (eg, in patients with 
diabetes and epilepsy), in many places 
replacing previous single gene tests. In 
microbiology, 16S and 18S rPCR is used 
in patients to identify micro- organisms.4 
In addition, whole exome and whole 
genome sequencing approaches are being 
introduced in, rare disease, critically ill 
patients in paediatric intensive care units, 
and routine whole genome sequencing 
of all childhood patients with cancer is 
due to start in the NHS in 2020. How to 
validate such tests, best use such informa-
tion, counsel patients and characterise the 
impact on patient outcome, is an active 
area of research. In other cases, genes, 
signatures and proteins identified by high 
throughput technologies have led to the 
generation of specific cheap tests, such as 
immunohistochemical stains, to quickly 
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Figure 1 Visual representation of translational medical research. In green boxes are different stages and types of research from the original 
question/challenge to change in practice. In blue are highlighted advances and in yellow the infrastructure facilitating improved research for 
children.
evaluate for certain markers of disease and in areas 
such as paediatric brain tumours, advanced molecular 
profiling has revolutionised both the classification and 
diagnosis of some tumour types.9
However, it is not just molecular testing, advances 
in imaging, such as MR spectroscopy,10 enable us to 
understand more and get greater precision with non- 
invasive tests. Neonatal MRI is giving us new informa-
tion and becoming more widespread, though how best 
to use this in the ‘real world’ remains a challenge.11 
The use of MRI micro- CT postmortem is enabling 
non- invasive evaluation of autopsy to the histological 
level.12 With such rapid advances in technologies, the 
challenge for the paediatrician is in understanding the 
relative benefits, limitations and costs of this extensive 
array of novel diagnostic tests.
improving therapies
Along with advances in technologies and improved 
understanding the biology comes the development 
of new therapies and therapeutic strategies. Notable 
examples include the development of genetically 
engineered CAR- T cell therapy as a strategy to cure 
relapsed acute leukaemia13 as well as disease modi-
fiers in cystic fibrosis, both now with established 
uses in clinical practice. With such therapies, such as 
CAR- T cells, there has been a need to study, under-
stand and develop appropriate management strategies 
for different patterns of side effects, such as the use 
of anti- IL6 agents to treat cytokine release syndrome/
storm. Other new therapies we have covered include 
oncolytic viruses, a novel approach to specifically 
targeting cancer cells.14
The evaluation of many of these advances, as well as 
the refinement of existing approaches, is dependent on 
high quality clinical trials. Novel trial designs15 16 and 
the use of harmonised outcome measures17 are helping 
more efficiently translate these. Importantly, a focus 
on what are important outcome measure are important 
for patients18 will be essential for both engagement 
with and the success of future clinical trials.
improving infrastrUctUre
To maximise the opportunities of all this work requires 
good infrastructure. The 100K genome project,19 
institutions such as clinical trials units20 and research 
networks form centres of expertise to support trials. 
There are now a multitude of training opportunities 
for trainees in the UK to gain experience in research, 
from the formal NIHR programmes,21 to specialty 
led22 to trainee led research networks and ‘virtual 
academic units’.23 24 At the centre of all care and 
research is the patient, and ongoing engagement of, 
and partnership with patients25 26 in driving and deliv-
ering research is an essential component to ensure that 
these advances lead to the improvements in health and 
quality of life that are required for by our patients. 
Alongside this, regulations and ethical frameworks 
ensure that patients are kept safe, research facilitated 
and incentives to promote industry to engage in paedi-
atric research.
conclUsion
This article provides a brief taster of the diverse types 
of research, methodologies and advances currently 
occurring in paediatrics. While paediatric oncology and 
neonatology have often led the way, advances are accel-
erating across all areas of child health. As often high-
lighted, engagement with research is not an ‘optional 
extra’ for paediatricians, rather a core component of 
working for the best for our patients. How to deliver 
this, including navigating the ethical frameworks and 
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a framework to design and review research involving 
children, is outlined in a recent series of articles in 
Archives of Disease in Childhood.26–29
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